Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

被引：0

作者：

Chatzikonstantinou, Thomas ^{[1
]}

Scarfo, Lydia ^{[2
,3
]}

Minga, Eva ^{[1
]}

Karakatsoulis, Georgios ^{[1
]}

Chamou, Dimitra ^{[1
]}

Kotaskova, Jana ^{[4
,5
,6
]}

Iacoboni, Gloria ^{[7
]}

Demosthenous, Christos ^{[8
,9
]}

Albi, Elisa ^{[2
]}

Alcoceba, Miguel ^{[10
,11
]}

Al-Shemari, Salem ^{[12
]}

Aurran-Schleinitz, Therese ^{[13
]}

Bacchiarri, Francesca ^{[14
]}

Chatzileontiadou, Sofia ^{[15
]}

Collado, Rosa ^{[16
]}

Davis, Zadie ^{[17
]}

de Deus Santos, Marcos Daniel ^{[18
]}

Dimou, Maria ^{[19
]}

Dmitrieva, Elena ^{[20
]}

Donaldson, David ^{[21
]}

Dos Santos, Gimena ^{[22
]}

Dreta, Barbara ^{[23
]}

Efstathopoulou, Maria ^{[24
]}

El-Ashwah, Shaimaa ^{[25
]}

Enrico, Alicia ^{[26
]}

Frygier, Andrzej ^{[27
]}

Galimberti, Sara ^{[28
]}

Galitzia, Andrea ^{[29
]}

Gimeno, Eva ^{[30
]}

Guarente, Valerio ^{[31
,32
,33
]}

Guieze, Romain ^{[34
]}

Harrop, Sean ^{[35
]}

Hatzimichael, Eleftheria ^{[36
]}

Herishanu, Yair ^{[37
,38
]}

Hernandez-Rivas, Jose-angel ^{[39
]}

Jaksic, Ozren ^{[40
]}

Kalicinska, Elzbieta ^{[41
]}

Laribi, Kamel ^{[42
]}

Karakus, Volkan ^{[43
]}

Kater, Arnon P. ^{[44
]}

Kho, Bonnie ^{[45
]}

Kislova, Maria ^{[20
]}

Konstantinou, Eliana ^{[46
]}

Koren-Michowitz, Maya ^{[47
,48
]}

Kotsianidis, Ioannis ^{[49
]}

Kubova, Zuzana ^{[50
,51
]}

Labrador, Jorge ^{[52
]}

Lad, Deepesh ^{[53
]}

Laurenti, Luca ^{[54
,55
]}

Longval, Thomas ^{[56
]}

机构：

[1] Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki, Greece

[2] Univ Vita Salute San Raffaele, Milan, Italy

[3] IRCCS Osped San Raffaele, Milan, Italy

[4] Masaryk Univ, Cent European Inst Technol CEITEC, Brno, Czech Republic

[5] Masaryk Univ, Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[6] Masaryk Univ, Fac Med, Brno, Czech Republic

[7] Univ Hosp Vall dHebron, Dept Hematol, Barcelona, Spain

[8] G Papanicolaou Hosp, Hematol Dept, Thessaloniki, Greece

[9] G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece

[10] Univ Hosp Salamanca HUS IBSAL, Dept Haematol, CIBERONC CB16 12 00233, Salamanca, Spain

[11] Canc Res Ctr CIC IBMCC USAL CSIC, Salamanca, Spain

[12] Kuwait Univ, Fac Med, Dept Med, Kuwait, Kuwait

[13] Inst Paoli Calmettes, Dept Hematooncol, Marseille, France

[14] Univ Siena, Div Hematol, Siena, Italy

[15] AUTH, AHEPA Hosp, Dept Internal Med 1, Hematol Unit, Thessaloniki, Greece

[16] Fdn Invest Hosp Gen Univ Valencia, Consorcio Hosp Gen Univ Valencia, Serv Hematol, Valencia, Spain

[17] Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England

[18] Univ Fed Espirito St, Internal Med Dept, Vila Velha, ES, Brazil

[19] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Hematol & Bone Marrow Transplantat, Athens, Greece

[20] SP Botkins City Hosp, Dept Hematol Oncol & Chemotherapy, Moscow, Russia

[21] Belfast City Hosp, Clin Haematol, Belfast, North Ireland

[22] Hosp Clin Montevideo, Montevideo, Uruguay

[23] Univ Hosp Ctr Zagreb, Dept Internal Med, Div Hematol, Zagreb, Croatia

[24] Athens Med Ctr Psychikon Branch, Dept Haematol, Athens, Greece

[25] Mansoura Univ, Oncol Ctr, Mansoura, Egypt

[26] Hosp Italiano La Plata, La Plata, Buenos Aires, Argentina

[27] Hull York Med Sch, Kingston Upon Hull, England

[28] Univ Pisa, Dept Clin & Expt Med, Sect Hematol, Pisa, Italy

[29] Osped Oncol A Businco, ARNAS G Brotzu, Hematol & Stem Cell Transplantat Unit, Cagliari, Italy

[30] Hosp Mar, Dept Hematol, Barcelona, Spain

[31] Univ Perugia, Inst Hematol, Perugia, Italy

[32] Univ Perugia, Ctr Hematooncol Res, Perugia, Italy

[33] Santa Maria Misericordia Hosp, Perugia, Italy

[34] Estaing Univ Hosp, Dept Hematol & Cell Therapy, Clermont Ferrand, France

[35] Univ Melbourne, St Vincents Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[36] Univ Ioannina, Fac Med, Sch Hlth Sci, Dept Haematol, Ioannina, Greece

[37] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel

[38] Tel Aviv Univ, Fac Med, Tel Aviv, Israel

[39] Infanta Leonor Univ Hosp, Pathol Dept, Madrid, Spain

[40] Univ Hosp Dubrava, Dept Hematol, Zagreb, Croatia

[41] Wroclaw Med Univ, Dept & Clin Hematol Blood Neoplasms & Bone Marrow, Wroclaw, Poland

[42] Ctr Hosp Le Mans, Dept Hematol, Le Mans, France

[43] Antalya Training & Res Hosp, Antalya, Turkiye

[44] Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands

[45] Pamela Youde Nethersole Eastern Hosp, Dept Med, Chai Wan, Hong Kong, Peoples R China

[46] Univ Athens, Laikon Gen Hosp, Dept Haematol, Athens, Greece

[47] Shamir Med Ctr, Dept Hematol, Zerifin, Israel

[48] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[49] Democritus Univ Thrace, Univ Hosp Alexandroupolis, Dept Hematol, Alexandroupolis, Greece

[50] Palacky Univ, Fac Med & Dent, Dept Hematooncol, Olomouc, Czech Republic

来源：

HEMASPHERE | 2024年 / 8卷 / 09期

关键词：

VENETOCLAX; RITUXIMAB;

D O I：

10.1002/hem3.70004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[21] Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
Mauro, Francesca R.
Molica, Stefano
Laurenti, Luca
Cortelezzi, Agostino
Carella, Angelo M.
Zaja, Francesco
Chiarenza, Annalisa
Angrilli, Francesco
Nobile, Francesco
Marasca, Roberto
Musolino, Caterina
Brugiatelli, Maura
Piciocchi, Alfonso
Vignetti, Marco
Fazi, Paola
Gentile, Giuseppe
De Propris, Maria S.
Della Starza, Irene
Marinelli, Marilisa
Chiaretti, Sabina
Del Giudice, Ilaria
Nanni, Mauro
Albano, Francesco
Cuneo, Antonio
Guarini, Anna
Foa, Robin
LEUKEMIA RESEARCH, 2014, 38 (02) : 198 - 203
[22] Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group
Al-Sawaf, O.
Robrecht, S.
Bahlo, J.
Fink, A. M.
Cramer, P.
von Tresckow, J.
Maurer, C.
Bergmann, M.
Seiler, T.
Lange, E.
Kneba, M.
Stilgenbauer, S.
Doehner, H.
Kiehl, M. G.
Jaeger, U.
Wendtner, C. M.
Fischer, K.
Goede, V.
Hallek, M.
Eichhorst, B.
Hopfinger, G.
LEUKEMIA, 2017, 31 (10) : 2251 - 2253
[23] A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia
Hampel, Paul J.
Swaminathan, Mahesh
Rogers, Kerry A.
Parry, Erin M.
Burger, Jan A.
Davids, Matthew S.
Ding, Wei
Ferrajoli, Alessandra
Hyak, Jonathan M.
Jain, Nitin
Kenderian, Saad S.
Wang, Yucai
Wierda, William G.
Woyach, Jennifer A.
Parikh, Sameer A.
Thompson, Philip A.
BLOOD ADVANCES, 2024, 8 (10) : 2342 - 2350
[24] Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect VR CLL cohort study
Flowers, Christopher R.
Nabhan, Chadi
Kay, Neil E.
Mato, Anthony
Lamanna, Nicole
Farber, Charles M.
Davids, Matthew S.
Kiselev, Pavel
Swern, Arlene S.
Sullivan, Kristen
Flick, E. Dawn
Sharman, Jeff P.
LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2327 - 2335
[25] Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach
Stephens, Deborah M.
Ruppert, Amy S.
Blum, Kristie
Jones, Jeffrey
Flynn, Joseph M.
Johnson, Amy J.
Ji, Jia
Phelps, Mitch A.
Grever, Michael R.
Byrd, John C.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (03): : 423 - 427
[26] Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia
Rai, Kanti R.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
[27] Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study
Heerema, Nyla A.
Byrd, John C.
Dal Cin, Paola S.
Aquila, Marie L. Dell'
Koduru, Prasad R. K.
Aviram, Ayala
Smoley, Stephanie A.
Rassenti, Laura Z.
Greaves, Andrew W.
Brown, Jennifer R.
Rai, Kanti R.
Kipps, Thomas J.
Kay, Neil E.
Van Dyke, Daniel L.
CANCER GENETICS AND CYTOGENETICS, 2010, 203 (02) : 134 - 140
[28] Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies
Tuncer, Hande H.
Ghosh, Nilanjan
Fleury, Isabelle
Leslie, Lori A.
Manzoor, Beenish S.
Lamanna, Nicole
Eyre, Toby A.
Hill, Brian T.
Brown, Jennifer R.
Sinai, Wendy
Coombs, Catherine C.
Ujjani, Chaitra
Roeker, Lindsey E.
Emechebe, Nnadozie
Barr, Paul M.
Davids, Matthew S.
Martinez-Calle, Nicolas
Rhodes, Joanna M.
Lansigan, Frederick
Pearson, Laurie
Choi, Yun
Schuster, Stephen J.
Skarbnik, Alan P.
Fakhri, Bita
Coyle, Michael
Stephens, Deborah M.
Thompson, Meghan C.
Jensen, Christopher E.
Marx, Steven E.
Jawaid, Dureshahwar
Schuh, Anna
Pivneva, Irina
Watson, Talissa
Guerin, Annie
Shadman, Mazyar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S357 - S358
[29] Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)
Cramer, Paula
Langerbeins, Petra
Eichhorst, Barbara
Hallek, Michael
EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (01) : 9 - 18
[30] Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group
Goede, Valentin
Busch, Raymonde
Bahlo, Jasmin
Chataline, Viktoria
Kremers, Stephan
Mueller, Lothar
Reschke, Daniel
Schlag, Rudolf
Schmidt, Burkhard
Vehling-Kaiser, Ursula
Wedding, Ulrich
Stilgenbauer, Stefan
Hallek, Michael
LEUKEMIA & LYMPHOMA, 2016, 57 (03) : 596 - 603

← 1 2 3 4 5 →